

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* GRANADILLO PEDRO P			2. Issuer Name and Ticker or Trading Symbol HAEMONETICS CORP [HAE]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 09/17/2018			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
400 WOOD ROAD			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) BRAINTREE MA 02184								
(City) (State) (Zip)								

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	09/17/2018		M ⁽¹⁾		8,196	A	\$36.37	41,555 ⁽²⁾	D	
Common Stock	09/17/2018		M ⁽¹⁾		6,573	A	\$45.45	48,128 ⁽²⁾	D	
Common Stock	09/17/2018		M ⁽¹⁾		10,353	A	\$35.5	58,481 ⁽²⁾	D	
Common Stock	09/17/2018		S ⁽¹⁾		1,502	D	\$108.92 ⁽³⁾	56,979 ⁽²⁾	D	
Common Stock	09/17/2018		S ⁽¹⁾		3,696	D	\$110.11 ⁽⁴⁾	53,283 ⁽²⁾	D	
Common Stock	09/17/2018		S ⁽¹⁾		13,183	D	\$111.33 ⁽⁵⁾	40,100 ⁽²⁾	D	
Common Stock	09/17/2018		S ⁽¹⁾		11,812	D	\$113.16 ⁽⁶⁾	28,288 ⁽²⁾	D	
Common Stock	09/17/2018		S ⁽¹⁾		631	D	\$114.16 ⁽⁷⁾	27,657 ⁽²⁾	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Non-qualified Stock Option (Right to Buy)	\$36.37	09/17/2018		M ⁽¹⁾		8,196		07/27/2013 ⁽⁸⁾	07/27/2019	Common Stock	8,196	\$0	0	D	
Non-qualified Stock Option (Right to Buy)	\$45.45	09/17/2018		M ⁽¹⁾		6,573		07/24/2014 ⁽⁸⁾	07/24/2020	Common Stock	6,573	\$0	0	D	
Non-qualified Stock Option (Right to Buy)	\$35.5	09/17/2018		M ⁽¹⁾		10,353		07/23/2015 ⁽⁸⁾	07/23/2021	Common Stock	10,353	\$0	0	D	

Explanation of Responses:

- Transaction pursuant to an existing 10b5-1 trading plan.
- This number includes unvested restricted stock units previously reported.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$108.61 to \$109.33, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (7) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$109.79 to \$110.55, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$110.92 to \$111.88, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$112.51 to \$113.35, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$114 to \$114.44, inclusive.
- Grant to reporting person of right to buy shares of common stock exercisable 100 percent on the first anniversary of the date of grant.

/s/ Thomas V. Powers, attorney- 09/19/2018
in-fact for Mr. Granadillo

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.